We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
230 hedge funds and large institutions have $1.35B invested in ANI Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 63 increasing their positions, 76 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
135% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 20
27% more capital invested
Capital invested by funds: $1.07B → $1.35B (+$284M)
12% more funds holding
Funds holding: 205 → 230 (+25)
0.16% more ownership
Funds ownership: 91.85% → 92.01% (+0.16%)
17% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 76
38% less call options, than puts
Call options by funds: $535K | Put options by funds: $863K
Holders
230
Holders Change
+25
Holders Change %
+12.2%
% of All Funds
3.08%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.05%
New
47
Increased
63
Reduced
76
Closed
20
Calls
$535K
Puts
$863K
Net Calls
-$328K
Net Calls Change
+$81K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$12.6M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$10.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$9.94M |
| 4 |
JP Morgan Chase
New York
|
+$9.24M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.87M |
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$19.7M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$11.8M |
| 3 |
Millennium Management
New York
|
-$11M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.94M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$6.8M |
